ABBV— AbbVie Inc.
NYSEHealthcare · Drug Manufacturers - General
AbbVie Inc. (ABBV) stock trades at $234.76, up 2.07% on the day. With a market capitalization of $414.77 billion, ABBV is a mega-cap healthcare stock. It trades at a price-to-earnings (P/E) ratio of 115.1, a forward P/E of 14.5 and earnings per share (EPS) of $2.04. Over the most recent period the company reported 12% year-over-year revenue growth and a net profit margin of 5.8%. Below you'll find ABBV's full fundamentals, fair-value estimates, dividend history, earnings and our buy, hold or avoid verdict for 2026.
Price & Performance
Performance
Analysis & Verdict
AbbVie Inc. (ABBV) Stock Analysis 2026
Rule-based · Updated daily · Not financial advice
AbbVie Inc. (ABBV) operates in the Drug Manufacturers - General space within the Healthcare sector. With a market cap of $414.8B, it qualifies as a large-cap company. Growth is moderate and the business remains profitable, offering a balanced risk/reward profile compared to high-multiple peers.
- Forward P/E (14.5×) is lower than trailing P/E (115.1×) — analysts expect earnings to improve
- Revenue growth of 12% YoY shows solid business momentum
- Dividend yield of 2.95% provides consistent income on top of price appreciation
- Low beta of 0.31 — less volatile than the market, suitable for conservative portfolios
- High P/E of 115.1× implies high expectations already priced in — leaves little room for disappointment
- Earnings fell 46% YoY — profitability is under pressure
- Current ratio below 1 (0.80×) — short-term liabilities exceed current assets
Verdict
Buy / Hold
More positives than negatives. Fundamentals support holding while monitoring key risks.
AI Insight
Powered by ClaudeAI-generated analysis for informational purposes only. Not financial advice.
Fair Value Estimates
Current price: $234.76
Graham Number
√(22.5 × EPS × Book Value)
N/A
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$98.40
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
6/10
75% score
Pays dividends
13Y hist.13+ years of dividend history
Dividend consistency (5Y+)
13 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
Return on equity — measures how efficiently capital is used
Positive profit margin
5.8%Net profit margin must be positive — company earns more than it spends
Revenue growth (annual)
+12.4%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
-46.2%Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
Low financial leverage reduces risk of distress
Current ratio above 1
0.80×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$1.4B/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
2.95%Stock must distribute income to shareholders
Financials
Revenue & Results
Key Statistics
Earnings
Next Earnings
Jul 30, 2026
36
days
EPS (TTM)
$2.04
P/E (TTM)
115.1
Fwd P/E
14.5
SEC Filings & Reported Financials
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Insider Transactions
SEC Form 4 · officers, directors & 10% owners
Dividends & Income
Dividends
Current DY
2.95%
5Y Avg Annual
$5.5560
Last Payment
$1.7300
Ex-Date
04/15/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest04/15/2026 | 05/15/2026 | $1.7300 | 2.95% |
01/16/2026 | 02/15/2026 | $1.7300 | 2.95% |
10/15/2025 | 11/14/2025 | $1.6400 | 2.79% |
07/15/2025 | 08/14/2025 | $1.6400 | 2.79% |
04/15/2025 | 05/15/2025 | $1.6400 | 2.79% |
01/15/2025 | 02/14/2025 | $1.6400 | 2.79% |
10/15/2024 | 11/14/2024 | $1.5500 | 2.64% |
07/15/2024 | 08/14/2024 | $1.5500 | 2.64% |
Magic Number
Shares needed to self-fund your next purchase
$234.76
Price
$1.7300
Last div. (quarterly)
136
shares
Own 136 ABBV shares ($31,927.36) and each quarterly dividend pays for 1 new share — the snowball runs on its own.
Investment target
$31,927.36
New shares / year
+4 shares
Tools & Simulators
If You Had Invested…
Hypothetical return based on historical prices
* Dividend reinvestment calculated at ex-date price. For informational purposes only.
Discover
Related Assets
Healthcare
Related Articles
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Sector
Healthcare
Industry
Drug Manufacturers - General
Location
North Chicago, United States
Employees
57,000
ABBV — Frequently Asked Questions
Is AbbVie Inc. (ABBV) a good stock to buy in 2026?
AbbVie Inc. (ABBV) shows strengths such as revenue growth of 12%, while risks include a rich P/E of 115×. Whether ABBV is a good buy in 2026 depends on your time horizon and risk tolerance — review the full bull case, bear case and fair-value estimates above. This is informational analysis, not financial advice.
What is ABBV's stock price today?
AbbVie Inc. (ABBV) trades at $234.76, up 2.07% on the session. Prices on this page update throughout the trading day.
Does ABBV pay a dividend?
Yes. AbbVie Inc. pays an annual dividend of $6.92 per share, a dividend yield of 2.95%. The most recent ex-dividend date was July 15, 2026. Its payout ratio is about 326% of earnings.
Is ABBV overvalued?
With a P/E ratio of 115.1×, ABBV trades at a premium valuation for the healthcare sector. Its PEG ratio is 0.63 (below 1, which can signal growth at a reasonable price). See the Fair Value Estimates section above for Graham Number and dividend-based price targets.
What is ABBV's market cap?
AbbVie Inc. (ABBV) has a market capitalization of $414.77 billion, classifying it as a mega-cap stock in the Healthcare sector.
Disclaimer: This page — including any buy/hold/avoid view, fair value or price estimate — is generated from market data for informational and educational purposes only and does not constitute financial, investment or trading advice. Data may be delayed or inaccurate. Always do your own research and consult a licensed financial advisor before making any investment decision.